Myb 34.5
Alternative Names: Myb-34.5Latest Information Update: 12 Sep 2023
Price :
$50 *
At a glance
- Originator Massachusetts General Hospital
- Developer Karcinolys
- Class Antineoplastics; Oncolytic viruses
- Mechanism of Action Apoptosis stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Liver cancer; Pancreatic cancer
Most Recent Events
- 12 Sep 2023 Discontinued - Preclinical for Liver cancer (Inoperable/Unresectable) in USA (Parenteral)
- 12 Sep 2023 Discontinued - Preclinical for Pancreatic cancer (Late-stage disease) in USA (Intratumoural)
- 28 Feb 2019 No recent reports of development identified for preclinical development in Liver-cancer(Inoperable/Unresectable) in USA (Parenteral, Injection)